Table 4.

Prognostic factors for all-cause and HCC mortality after post-transplant recurrence in multivariable analyses.

	All-cause death*	P-value	HCC death*	P-value
Recur after 2 years	0.57 (0.24–0.77)	<0.001	0.46 (0.32–0.66)	<0.001
Treatment after recurrence
RFA vs. sorafenib	0.28 (0.12–0.63)	0.002	0.24 (0.07–0.81)	0.022
Transplantation periods
2009–2012 vs. before 2008	1.57 (1.03–2.38)	0.036	1.96 (1.19–3.22)	0.008
After 2013 vs. before 2008	1.24 (0.73–2.09)	0.426	1.87 (1.01–3.45)	0.047

*Data were adjusted hazard ratios (95% confidence intervals), adjusted for male sex, HBV, HCV, cirrhosis, diabetes, hyperlipidemia, alcohol use, living donor, monthly income, post-transplant medications, and other HCC treatments (hepatectomy, transarterial chemoembolization, radiotherapy, others) after recurrence.

RFA, radiofrequency ablation.